Holen Sie sich die Stockscreener-App
57.77
3.25%
-1.94
Handel nachbörslich:
57.77
Anaptysbio Inc Aktie (ANAB) Neueste Nachrichten
ANAB (ANAB) Form 144: Insider-linked 10,000-share sale disclosed - Stock Titan
AnaptysBio (ANAB) may find a bottom soon, here's why you should buy the stock now - MSN
J.P. Morgan Maintains AnaptysBio(ANAB.US) With Buy Rating, Raises Target Price to $70 - Moomoo
Affiliate sale notice: ANAB (NASDAQ: ANAB) plans 10,000-share sale - Stock Titan
AnaptysBio Inc (ANAB) Stock Price, Quote, News & History - Benzinga
ANAB Technical Analysis | Trend, Signals & Chart Patterns | ANAPTYSBIO INC (NASDAQ:ANAB) - ChartMill
Wall Street analysts see a 38.75% upside in AnaptysBio (ANAB): Can the stock really move this high? - MSN
AnaptysBio (NASDAQ: ANAB) moves fiscal year-end to June 30, 2026 - Stock Titan
AnaptysBio, Inc. Approves Change in Fiscal Year-End from December 31 to June 30 - marketscreener.com
[144] ANAPTYSBIO, INC SEC Filing - Stock Titan
Is AnaptysBio (ANAB) Outperforming Other Medical Stocks This Year? - Yahoo Finance UK
ANAB Stock Price, Quote & Chart | ANAPTYSBIO INC (NASDAQ:ANAB) - ChartMill
AnaptysBio, Inc. (NASDAQ:ANAB) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Dennis Mulroy (ANAB) files to sell 10,000 shares via option exercise - Stock Titan
Wall Street Analysts See a 38.75% Upside in AnaptysBio (ANAB): Can the Stock Really Move This High? - Yahoo Finance
AnaptysBio (ANAB) Valuation After Spin Off And Shift To Royalty Focused Model - Sahm
AnaptysBio (NASDAQ:ANAB) Downgraded to "Hold" Rating by Wall Street Zen - MarketBeat
Leerink Partners Maintains AnaptysBio(ANAB.US) With Buy Rating, Raises Target Price to $90 - Moomoo
Point72 Group Holds 55,303 ANAB Shares (0.2%) — ANAB (ANAB) - Stock Titan
Sirenia Capital discloses 1.92M shares of AnaptysBio (NASDAQ: ANAB) - Stock Titan
Vanguard Group Inc. Increases Position in AnaptysBio, Inc. $ANAB - MarketBeat
Emily Bodnar Reiterates Buy on AnaptysBio, Keeps $30 Price Target on ANB033 Progress and Solid Cash Runway - TipRanks
AnaptysBio appoints Christopher Murphy as CFO - MSN
AnaptysBio: Daniel Faga Is Anticipated to Be the Initial CEO for Spin-Off >ANAB - Moomoo
AnaptysBio (ANAB) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance
HighMark Wealth Management LLC Has $4.56 Million Position in AnaptysBio, Inc. $ANAB - MarketBeat
AnaptysBio (ANAB) director Owen Hughes receives 11,250 RSU equity grant - Stock Titan
AnaptysBio (NASDAQ: ANAB) director Hughes Owen files initial Form 3 insider report - Stock Titan
AnaptysBio (NASDAQ: ANAB) grants CFO 25,765 restricted stock units - Stock Titan
AnaptysBio (NASDAQ: ANAB) CFO Christopher Murphy files initial Form 3 - Stock Titan
ANAB Maintained by Barclays -- Price Target Raised to $75.00 - GuruFocus
ANAB Maintained by UBS -- Price Target Raised to $76.00 - GuruFocus
AnaptysBio Faces Pressure As Market Reacts to Update Today - Kalkine Media
UBS Adjusts Price Target on AnaptysBio to $76 From $70, Maintains Buy Rating - Moomoo
A Quick Look at Today's Ratings for AnaptysBio(ANAB.US), With a Forecast Between $75 to $93 - Moomoo
AnaptysBio (NASDAQ:ANAB) Trading Down 7.7% After Earnings Miss - MarketBeat
AnaptysBio stock rallies as Delaware court tosses Tesaro breach claim - MSN
AnaptysBio, Inc. Stock 12‑Month Price Target Raised to $70.54, Implies 8% Upside - TradingView
AnaptysBio, Inc. Stock 12‑Month Price Target Raised to $69.09, Implies 5% Upside - TradingView
TD Cowen Maintains AnaptysBio(ANAB.US) With Buy Rating, Maintains Target Price $75 - Moomoo
AnaptysBio (ANAB) Swings Back To Q1 Loss Per Share Challenging Recent Profitability Hopes - Sahm
ANAB SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
Anaptys (ANAB) Posts Strong Q1 Revenue Surpassing Expectations - GuruFocus
Nektar Therapeutics Raises $374 Million After Alopecia Data Release; AnaptysBio’s First Tracks Bio Debuts on NASDAQ - geneonline.com
Is AnaptysBio (ANAB) 51.9% Undervalued After Q1 2026 EPS/Revenue - GuruFocus
AnaptysBio (NASDAQ:ANAB) Releases Earnings Results, Misses Expectations By $1.20 EPS - MarketBeat
AnaptysBio, Inc. (ANAB) Misses Q1 EPS by 88c - StreetInsider
AnaptysBio Appoints New CFO and Board Director - The Globe and Mail
AnaptysBio (NASDAQ: ANAB) shifts to royalty focus after Q1 2026 loss - Stock Titan
AnaptysBio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Earnings Flash (ANAB) AnaptysBio, Inc. Reports Q1 Revenue $25.6M, vs. FactSet Est of $18.9M - marketscreener.com
AnaptysBio (NASDAQ: ANAB) pivots to royalties and launches $100M buyback - Stock Titan
BRIEF-AnaptysBio Q1 Net Income USD -52.884 Million - TradingView
Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update - Yahoo Finance
AnaptysBio Appoints Chris Murphy as CFO, Owen Hughes to Board - Moomoo
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):